Company / Capital Expenditures
Johnson & Johnson Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$4.8B
FY2025
5-year range
$3.7B / $4.8B
FY2021-FY2025
Trend
+9.2%
vs FY2024
Sector context
#1 of 195
Health Care
What the data says
Among 195 Health Care companies, Johnson & Johnson is in the top 1% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $3.2B in FY2016 to $4.8B in FY2025.
Based on SEC 10-K filings.
$4.8B in FY2025 with a 5-year CAGR of +7.6%. Ranks 1st among 195 companies in Health Care.
Improved from $4.5B to $4.8B over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +6.4%
- 5-Year CAGR
- +7.6%
- 10-Year CAGR
- -
Sector benchmark
+4033.0% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.6%, indicating consistent growth.
- In FY2025, capital expenditures increased 9.2% year-over-year.
- Ranks #1 out of 195 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 27.3%
- Strong return on equity: 31.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.8B | +9.2% |
| FY2024 | $4.4B | -2.6% |
| FY2023 | $4.5B | +13.3% |
| FY2022 | $4.0B | +9.8% |
| FY2021 | $3.7B | +9.1% |
| FY2020 | $3.3B | -4.3% |
| FY2019 | $3.5B | -4.7% |
| FY2018 | $3.7B | +11.9% |
| FY2017 | $3.3B | +1.6% |
| FY2016 | $3.2B | -6.8% |
As of FY2025 · SEC 10-K · Updated Mar 11, 2026